Chargement en cours...
Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
OBJECTIVE: Metabolic syndrome refers to a collection of risk factors associated with the development of cardiovascular disease and type 2 diabetes mellitus (T2DM). Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight and blood pressure (BP) in...
Enregistré dans:
| Publié dans: | Diabetes Metab Syndr Obes |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5291455/ https://ncbi.nlm.nih.gov/pubmed/28184166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S126291 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|